ZFYVE21

ZFYVE21 is an endosome-associated Rab5 effector that couples membrane trafficking to multiple signaling outputs governing vascular inflammation, endothelial homeostasis, and tumor cell motility (PMID:31113953). It localizes to early endosomes in a Rab5- and PI(3)P-dependent manner following membrane attack complex stimulation, where it is post-translationally stabilized (PMID:31113953). At these endosomes ZFYVE21 directs SMURF2-mediated polyubiquitinylation and proteasomal degradation of endosomal PTEN, enriching vesicular PI(3,4,5)P3 and recruiting activated Akt and NIK to drive non-canonical NF-κB signaling (PMID:31113953). It additionally assembles a 'ZRR' complex with Rubicon and RNF34 on early endosomes, in which Rubicon disrupts caspase-1 association with its pseudosubstrate Flightless I and RNF34 ubiquitinylates and degrades FliI, thereby licensing endosome-associated caspase-1 for NLRP3 inflammasome activation in endothelial cells (PMID:37225719); this inflammasome axis is also engaged downstream of Hedgehog-induced ZFYVE21 in memory T cells to amplify IFN-γ responses (PMID:36943921). ZFYVE21 further sustains endothelial nitric oxide production by reducing vesicular caveolin-1 and facilitating Rab5/Akt-dependent transfer of Golgi-derived eNOS to a perinuclear vesicular pool, maintaining vascular barrier function (PMID:38797325). In adherent and tumor cells, ZFYVE21 (ZF21) localizes to focal adhesions and binds FAK, β-tubulin, m-calpain, and SHP-2; through its N-terminal FAK interaction and a C-terminal noncanonical PH-like domain it promotes FAK Tyr397 dephosphorylation, focal adhesion disassembly, MT1-MMP-dependent invadopodia activity, cell migration, and experimental lung metastasis (PMID:20439989, PMID:21768110, PMID:32976654).

1. 2010 High

   Established the first molecular function for ZF21/ZFYVE21 by showing it acts at focal adhesions to drive their disassembly, answering how the protein influences cell motility.

   Evidence siRNA knockdown, reciprocal Co-IP with FAK, immunofluorescence, nocodazole-induced FA disassembly and migration assays

   PMID:20439989

   Open questions at the time

   • Does not define which domain mediates FAK binding versus phosphatase recruitment
   • Mechanism of FAK Tyr397 dephosphorylation (direct vs adaptor) not resolved
2. 2011 High

   Defined the binding repertoire and an unusual structural feature, showing ZF21 engages FAK, β-tubulin, m-calpain, and SHP-2 and that its C-terminus is a noncanonical PH-like domain lacking a phosphoinositide-binding interface yet required for migration and metastasis.

   Evidence Co-IP, NMR structure determination of C-terminal domain, deletion-mutant functional assays, in vivo lung metastasis model; complementary proteomic Co-IP/MS identifying 45 partners including SIC RNA-binding proteins

   PMID:20890123 PMID:21768110

   Open questions at the time

   • Functional roles of most proteomically identified partners untested
   • How a PH-like domain without a phosphoinositide interface contributes mechanistically is unexplained
3. 2013 Medium

   Extended ZF21 function from FA disassembly to invasion by showing it controls MT1-MMP delivery to invadopodia, linking it to ECM degradation.

   Evidence siRNA knockdown, gelatin degradation assays, MT1-MMP immunofluorescence, zymography

   PMID:23382803

   Open questions at the time

   • How ZF21 directs MT1-MMP localization without altering its production is unknown
   • Single lab, no in vivo confirmation in this study
4. 2019 High

   Reframed ZFYVE21 as an endosomal Rab5 effector and connected it to inflammatory signaling, showing it degrades endosomal PTEN via SMURF2 to activate Akt–NIK–non-canonical NF-κB after complement attack.

   Evidence Endosomal fractionation, co-localization imaging, pharmacologic PI manipulation, reciprocal Co-IP, ubiquitination assays, humanized mouse model

   PMID:31113953

   Open questions at the time

   • Relationship between the endosomal signaling role and the focal-adhesion role is unintegrated
   • Stoichiometry and direct binding within the ZFYVE21–SMURF2–PTEN module not fully resolved
5. 2020 Medium

   Mapped the FAK-binding determinant to the ZF21 N-terminus and demonstrated, via competitive inhibition, that this interaction is necessary for both FA turnover and invadopodia activity.

   Evidence Dominant-negative N-terminal peptide expression, FA turnover assays, Matrigel invasion, in vivo lung metastasis model

   PMID:32976654

   Open questions at the time

   • Whether the N-terminal fragment acts solely by blocking FAK binding is not excluded
   • Does not address endosomal functions of the N-terminus
6. 2023 High

   Identified a defined inflammasome-activating complex (ZRR) and a Hedgehog-driven T cell circuit, explaining how endosomal ZFYVE21 promotes NLRP3 activation in two cell types.

   Evidence Inflammasome proteomics, Co-IP, ubiquitination assays, multiple in vivo mouse models and human tissue (ZRR/FliI); humanized mice, primary T cell culture, Hh stimulation, T cell-specific manipulation (Hh axis)

   PMID:36943921 PMID:37225719

   Open questions at the time

   • Direct binding topology within the Rubicon–RNF34–ZFYVE21 complex not fully mapped
   • Whether the T cell and endothelial inflammasome mechanisms are identical is untested
7. 2024 High

   Demonstrated a vascular-protective trafficking role, showing ZFYVE21 sustains eNOS activity by lowering inhibitory caveolin-1 and routing Golgi-derived eNOS to Rab5+ vesicles, with loss causing kidney insufficiency and accelerated aging.

   Evidence EC-specific knockout mice, live-cell imaging, human kidney organ cultures, nitric oxide donor rescue, fractionation/localization

   PMID:38797325

   Open questions at the time

   • Mechanism by which ZFYVE21 reduces vesicular caveolin-1 is unspecified
   • Connection to its PTEN/NF-κB and inflammasome axes within the same cell not delineated

• How a single endosomal Rab5 effector is partitioned between its focal-adhesion/invadopodia functions and its distinct endosomal signaling complexes (PTEN/NF-κB, ZRR/inflammasome, eNOS trafficking) within a given cell remains unresolved.
• No unified model linking the cytoskeletal and endosomal activities
• Domain-level rules governing which partner complex assembles in which context are unknown